Search results
Results from the WOW.Com Content Network
In addition, there is continuing research and development of new dual α/δ and γ/δ PPAR agonists for additional therapeutic indications, as well as "pan" agonists acting on all three isoforms. [7] [8] The anti-hypertension drug telmisartan is known to have PPAR γ/δ dual partial agonist activity in vivo. It also activates PPAR-α in vitro. [9]
Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG), also known as the glitazone reverse insulin resistance receptor, or NR1C3 (nuclear receptor subfamily 1, group C, member 3) is a type II nuclear receptor functioning as a transcription factor that in humans is encoded by the PPARG gene.
PPAR -alpha and -gamma pathways. In the field of molecular biology, the peroxisome proliferator–activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. [1]
This category lists drugs that act as agonists on peroxisome proliferator-activated receptors (PPARs). Subcategories This category has the following 2 subcategories, out of 2 total.
Leriglitazone is a PPAR-gamma agonist and metabolite of the glitazone pioglitazone. It is developed for adrenomyeloneuropathy, and other neurodegenerative diseases ...
It is a first in class drug which acts as a dual PPAR agonist at the subtypes α (alpha) and γ (gamma) of the peroxisome proliferator-activated receptor (PPAR). Agonist action on PPARα lowers high blood triglycerides, and agonist action on PPARγ improves insulin resistance and consequently lowers blood sugar. [2]
Lobeglitazone (trade name Duvie, Chong Kun Dang) is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin. [3]
Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) receptor agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously. [ 1 ] [ 2 ] [ 3 ] As of 2023, it is in a phase III trial for nonalcoholic steatohepatitis ; its advantage over other drugs that are in phase III trials for the ...